W

‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

Business Management
Share
‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

The Federal Trade Commission and seven states say Shkreli should be held in contempt

‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

Source：MarketWatch

Disclaimer：Please read market information rationally and stay aware of investment risks. All content on this site is for informational purposes only and does not constitute investment advice.

Related Reading

An AI label alone no longer wins lenders, JPMorgan says

As default insurance on several AIlinked firms hits record costs, companies must show they can finance investment, service the debt and eventually mint cash,…

Binance files for Brazil crypto license ahead of Friday deadline

The exchange is delisting 22 crypto assets for Brazilian users and hopes talks with the central bank will allow it to restore some services.…

Solana bug reports now cost 1 SOL as AI floods security teams with spam

Researchers must now permanently burn 1 SOL for every submission after a monthlong contest drew 809 reports, with AI believed to have helped generate or write…

Bitcoin ETFs claw back $110M after $774M exit

US spot Bitcoin ETFs remained in the red for October, with about $202 million in net outflows for the month despite Monday’s rebound. Source：Cointelegraph

Source：https://www.marketwatch.com/story/pharma-bro-martin-shkreli-is-in-trouble-with-regulators-again-this-time-for-influencing-biopharma-stocks-7356c3bb